These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36443694)

  • 1. The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study.
    Zhang C; Wu B; Yang H; Yao Z; Zhang N; Tan F; Liu M; Xu K; Chen L; Xing J; Cui M; Su X
    BMC Cancer; 2022 Nov; 22(1):1223. PubMed ID: 36443694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 3. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer.
    Sah BK; Zhang B; Zhang H; Li J; Yuan F; Ma T; Shi M; Xu W; Zhu Z; Liu W; Yan C; Li C; Liu B; Yan M; Zhu Z
    Nat Commun; 2020 Nov; 11(1):6093. PubMed ID: 33257672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial.
    Pan L; Tian Y; Wang K; Tang J; Liu J; Zhang J; Wang M; Liu J; Xu H; Chen X
    J Gastrointest Oncol; 2022 Dec; 13(6):3300-3313. PubMed ID: 36636043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
    Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients.
    Ota M; Saeki H; Uehara H; Matsuda Y; Tsutsumi S; Kusumoto T; Yasui H; Ubukata Y; Yamaguchi S; Orita H; Izawa N; Kakizoe S; Shimokawa M; Yoshizumi T; Kakeji Y; Mori M; Oki E
    Int J Clin Oncol; 2023 Sep; 28(9):1166-1175. PubMed ID: 37368093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Locally Advanced Gastric Cancer Responding to Neoadjuvant Chemotherapy with Ramucirumab plus Paclitaxel-Case Report].
    Matsui H; Shimizu Y; Tachikawa H; Homma T; Mizukami T; Hashimoto T; Abe H
    Gan To Kagaku Ryoho; 2019 Oct; 46(10):1565-1567. PubMed ID: 31631140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 9. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.
    Beeharry MK; Ni ZT; Yang ZY; Zheng YN; Feng RH; Liu WT; Yan C; Yao XX; Li C; Yan M; Zhu ZG
    BMC Cancer; 2020 Mar; 20(1):224. PubMed ID: 32183736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.
    Jiang Q; Liu W; Zeng X; Zhang C; Du Y; Zeng L; Yin Y; Fan J; Yang M; Tao K; Zhang P
    Front Immunol; 2023; 14():1122121. PubMed ID: 37215127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The short-term efficacy of neoadjuvant SOX versus SOX plus immune checkpoint inhibitor following laparoscopic gastrectomy for locally advanced gastric cancer: a multicenter retrospective cohort study in China.
    Cui H; Yang Y; Song L; Yuan Z; Sun L; Du J; Lu Y; Ning N; Cui J; Shi Y; Chen L; Wei B
    Cancer Immunol Immunother; 2024 Sep; 73(11):216. PubMed ID: 39235478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma.
    Wang Z; He T; Yu D; Qin X; Geng A; Yang H
    Exp Ther Med; 2022 Oct; 24(4):625. PubMed ID: 36160880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study.
    Ma J; Yao S; Li XS; Kang HR; Yao FF; Du N
    Medicine (Baltimore); 2015 Oct; 94(42):e1489. PubMed ID: 26496252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial.
    Wang X; Lu C; Wei B; Li S; Li Z; Xue Y; Ye Y; Zhang Z; Sun Y; Liang H; Li K; Zhu L; Zheng Z; Zhou Y; He Y; Li F; Wang X; Liang P; Huang H; Li G; Shen X; Ji J; Tang Y; Xu Z; Chen L;
    J Hematol Oncol; 2024 Apr; 17(1):17. PubMed ID: 38589926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the efficacy and influencing factors of preoperative P-SOX neoadjuvant chemotherapy regimen for progressive gastric cancer-construction of a clinical prediction model.
    Feng L; Shao L; Sun S; Zhang C; Cai B
    Cancer Med; 2023 Jun; 12(12):13031-13040. PubMed ID: 37096925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety evaluation of PSOX, DOF and SOX regimens as neoadjuvant chemotherapy for advanced gastric cancer.
    Yu P; Zhu S; Pu Y; Cai B; Ma X; Zhang C
    Future Oncol; 2022 Dec; 18(40):4483-4492. PubMed ID: 36916454
    [No Abstract]   [Full Text] [Related]  

  • 17. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
    Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis.
    Zhang X; Huang H; Wei Z; Zhu Z; Yang D; Fu H; Xu J; Hu Z; Zhang Y; You Q; Huang X; Yan R; Wang W; Cai Q
    Cancer Manag Res; 2020; 12():6641-6653. PubMed ID: 32801898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial.
    Yu J; Gao Y; Chen L; Wu D; Shen Q; Zhao Z; Liu W; Yang H; Zhang Q; Wang X; Hu P; Zheng Z; Wang X; Liu H; Xu Z; Yan Z; Wu Y; Jin M; Zhang Q; Liu X; Zhu K; Shou C
    JAMA Netw Open; 2022 Feb; 5(2):e220426. PubMed ID: 35226081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601.
    Iwatsuki M; Orita H; Kobayashi K; Hidaka S; Arigami T; Kusumoto T; Satake H; Oki E; Tsutsumi S; Tobimatsu K; Shimokawa M; Saeki H; Makiyama A; Baba H; Mori M
    Gastric Cancer; 2022 Jan; 25(1):180-187. PubMed ID: 34379229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.